Payment overview · 2025
General Payments
$295.89
16 reported records · 12 companies
Healthcare provider profile · identity verified
David L Harrison, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CRESTVIEW, FL · NPI 1497702302
Verified facts
What the public records show
CMS Open Payments records show David L Harrison, MD received $295.89 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.66 | 19.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $43.19 | 14.6% | 2 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $31.99 | 10.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.51 | 10.0% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $20.83 | 7.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.66 | 7.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.33 | 6.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.83 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.11 | 5.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.00 | 4.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.00 | 4.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.78 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $295.89 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.66 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.66 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $43.19 | 2 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $31.99 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.51 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 501 | 77 |
| Furosemide | Furosemide | 448 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 447 | 74 |
| Gabapentin | Gabapentin | 403 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 380 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 378 | 55 |
| Eliquis | Apixaban | 374 | 37 |
| Potassium Chloride | Potassium Chloride | 261 | 50 |
| Memantine Hcl | Memantine Hcl | 260 | 32 |
| Omeprazole | Omeprazole | 252 | 36 |
| Lisinopril | Lisinopril | 215 | 30 |
| Myrbetriq | Mirabegron | 215 | 12 |
| Donepezil Hcl | Donepezil Hcl | 208 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 35 |
| Famotidine | Famotidine | 194 | 27 |
| Levetiracetam | Levetiracetam | 183 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 33 |
| Losartan Potassium | Losartan Potassium | 170 | 28 |
| Montelukast Sodium | Montelukast Sodium | 165 | 23 |
| Carvedilol | Carvedilol | 161 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 25 |
| Xarelto | Rivaroxaban | 135 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 16 |
| Linzess | Linaclotide | 127 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 27 |
| Mirtazapine | Mirtazapine | 111 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 21 |
| Trazodone Hcl | Trazodone Hcl | 109 | 17 |
| Metformin Hcl | Metformin Hcl | 97 | 14 |
| Sertraline Hcl | Sertraline Hcl | 96 | 15 |
| Allopurinol | Allopurinol | 94 | 12 |
| Prednisone | Prednisone | 94 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 14 |
| Clonidine Hcl | Clonidine Hcl | 89 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 11 |
| Januvia | Sitagliptin Phosphate | 78 | suppressed |
| Novolog | Insulin Aspart | 78 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 76 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 12 |
| Spironolactone | Spironolactone | 76 | suppressed |
| Lactulose | Lactulose | 72 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 71 | 16 |
| Jantoven | Warfarin Sodium | 69 | suppressed |
| Meloxicam | Meloxicam | 68 | 11 |
| Simvastatin | Simvastatin | 68 | suppressed |
| Glimepiride | Glimepiride | 66 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 66 | suppressed |
| Nifedipine Er | Nifedipine | 64 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 38 |
| Amiodarone Hcl | Amiodarone Hcl | 60 | suppressed |
| Brilinta | Ticagrelor | 59 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | suppressed |
| Atenolol | Atenolol | 56 | suppressed |
| Latanoprost | Latanoprost | 55 | 14 |
| Finasteride | Finasteride | 54 | suppressed |
| Ondansetron Odt | Ondansetron | 54 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 11 |
| Memantine Hcl Er | Memantine Hcl | 52 | suppressed |
| Topiramate | Topiramate | 52 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 51 | 17 |
| Movantik | Naloxegol Oxalate | 48 | suppressed |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Sucralfate | Sucralfate | 47 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Nystop | Nystatin | 44 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | 13 |
| Primidone | Primidone | 41 | suppressed |
| Torsemide | Torsemide | 40 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 39 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 16 |
| Levemir | Insulin Detemir | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Humalog | Insulin Lispro | 33 | suppressed |
| Xifaxan | Rifaximin | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 29 |
| Fluorometholone | Fluorometholone | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | 13 |
| Baclofen | Baclofen | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Secuado | Asenapine | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | 11 |
| Nuplazid | Pimavanserin Tartrate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 19 | suppressed |
| Austedo | Deutetrabenazine | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 18 |
| Estradiol | Estradiol | 18 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Veozah | Fezolinetant | 18 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pentasa | Mesalamine | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Sotalol Af | Sotalol Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Riluzole | Riluzole | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $295.89 · 16 records | Lilly USA, LLC | CARTO 3, FARXIGA, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, OTEZLA, REPATHA, SKYCLARYS, The Cologuard Plus Collection Kit, VOWST, XIFAXAN, ZEPBOUND, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error